Comprehensive analysis reveals the prognostic and immunological role of PSMD13 in hepatocellular carcinoma.

IF 2.7 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Mammalian Genome Pub Date : 2024-12-30 DOI:10.1007/s00335-024-10097-6

Yun Li, Honghui Liu, Na Liu, Lin Chen, Ruijie Liu

{"title":"Comprehensive analysis reveals the prognostic and immunological role of PSMD13 in hepatocellular carcinoma.","authors":"Yun Li, Honghui Liu, Na Liu, Lin Chen, Ruijie Liu","doi":"10.1007/s00335-024-10097-6","DOIUrl":null,"url":null,"abstract":"<p><p>Immune cell infiltration in liver hepatocellular carcinoma (LIHC) is promising for immunotherapy. However, effective predictive markers to accurately predict a tumour's immune status are lacking. PSMD13, a native component of the 26 S proteasome subunit involved in intracellular metabolism, has an unclear association with cancer and immunity. Using bioinformatics analysis of data from the TCGA, we investigated the expression patterns, prognostic values, gene functions, and tumour immune relationships of PSMD13 in LIHC. We developed a prognostic model that incorporates PSMD13 for LIHC and validated the biological functions of PSMD13 in LIHC cells. Furthermore, we analysed the associations between PSMD13 expression and the tumour immune markers CD206 and CD8 in 101 paired liver tissues using immunohistochemistry. PSMD13 was upregulated in LIHC and served as a prognostic biomarker of LIHC. The knockdown of PMSD13 significantly affected the proliferation, migration, and colony formation of LIHC cells. PSMD13 was closely associated with the infiltration of M2 macrophages and the expression of various tumour immune checkpoints. Our study revealed that PSMD13 is a crucial component contributing to the malignant behaviour of LIHC, indicating its essential role in both the prognosis and potential immune microenvironment profile of LIHC.</p>","PeriodicalId":18259,"journal":{"name":"Mammalian Genome","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mammalian Genome","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s00335-024-10097-6","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immune cell infiltration in liver hepatocellular carcinoma (LIHC) is promising for immunotherapy. However, effective predictive markers to accurately predict a tumour's immune status are lacking. PSMD13, a native component of the 26 S proteasome subunit involved in intracellular metabolism, has an unclear association with cancer and immunity. Using bioinformatics analysis of data from the TCGA, we investigated the expression patterns, prognostic values, gene functions, and tumour immune relationships of PSMD13 in LIHC. We developed a prognostic model that incorporates PSMD13 for LIHC and validated the biological functions of PSMD13 in LIHC cells. Furthermore, we analysed the associations between PSMD13 expression and the tumour immune markers CD206 and CD8 in 101 paired liver tissues using immunohistochemistry. PSMD13 was upregulated in LIHC and served as a prognostic biomarker of LIHC. The knockdown of PMSD13 significantly affected the proliferation, migration, and colony formation of LIHC cells. PSMD13 was closely associated with the infiltration of M2 macrophages and the expression of various tumour immune checkpoints. Our study revealed that PSMD13 is a crucial component contributing to the malignant behaviour of LIHC, indicating its essential role in both the prognosis and potential immune microenvironment profile of LIHC.

查看原文本刊更多论文

综合分析揭示PSMD13在肝细胞癌中的预后和免疫学作用。

肝脏肝细胞癌（LIHC）的免疫细胞浸润是一种有前景的免疫治疗方法。然而，目前还缺乏有效的预测标记物来准确预测肿瘤的免疫状态。PSMD13是参与细胞内代谢的26 S蛋白酶体亚基的天然成分，与癌症和免疫的关系尚不清楚。利用TCGA数据的生物信息学分析，我们研究了PSMD13在LIHC中的表达模式、预后价值、基因功能和肿瘤免疫关系。我们开发了一个包含PSMD13的LIHC预后模型，并验证了PSMD13在LIHC细胞中的生物学功能。此外，我们利用免疫组织化学分析了101对肝脏组织中PSMD13表达与肿瘤免疫标志物CD206和CD8之间的关系。PSMD13在LIHC中上调，并作为LIHC的预后生物标志物。PMSD13的敲低显著影响LIHC细胞的增殖、迁移和集落形成。PSMD13与M2巨噬细胞的浸润及各种肿瘤免疫检查点的表达密切相关。我们的研究表明PSMD13是促成LIHC恶性行为的关键成分，表明其在LIHC的预后和潜在的免疫微环境谱中都起着重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mammalian Genome 生物-生化与分子生物学

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Mammalian Genome focuses on the experimental, theoretical and technical aspects of genetics, genomics, epigenetics and systems biology in mouse, human and other mammalian species, with an emphasis on the relationship between genotype and phenotype, elucidation of biological and disease pathways as well as experimental aspects of interventions, therapeutics, and precision medicine. The journal aims to publish high quality original papers that present novel findings in all areas of mammalian genetic research as well as review articles on areas of topical interest. The journal will also feature commentaries and editorials to inform readers of breakthrough discoveries as well as issues of research standards, policies and ethics.